RGEDF (Chemical Works of Gedeon Richter) 3-Year RORE % : -16.32% (As of Dec. 2025)


RGEDF Chemical Works of Gedeon Richter PLC RGEDF
94 GF Score
Price $39.76
GF Value $35.24
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Chemical Works of Gedeon Richter 3-Year RORE %?

Chemical Works of Gedeon Richter RGEDF +0.30% 94 3-Year RORE % is -16.32 as of Dec. 2025. GuruFocus rates RGEDF with a GF Score™ of 94/100 and a GF Value™ of $35.24 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 936 Drug Manufacturers companies, Chemical Works of Gedeon Richter ranks worse than 65.38% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Chemical Works of Gedeon Richter's 3-Year RORE % for the quarter that ended in Dec. 2025 was -16.32%.

The industry rank for Chemical Works of Gedeon Richter's 3-Year RORE % or its related term are showing as below:

RGEDF's 3-Year RORE % is ranked worse than
65.38% of 936 companies
in the Drug Manufacturers industry
Industry Median: 3.075 vs RGEDF: -16.32

Chemical Works of Gedeon Richter  (OTCPK:RGEDF) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Chemical Works of Gedeon Richter 3-Year RORE % Related Terms


Chemical Works of Gedeon Richter 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Chemical Works of Gedeon Richter's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chemical Works of Gedeon Richter 3-Year RORE % Chart

Chemical Works of Gedeon Richter Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.39 20.15 6.38 -8.76 -16.32

Chemical Works of Gedeon Richter Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.54 -8.76 -8.77 -0.41 -16.32

RGEDF vs ZTS, UTHR, VTRS: 3-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Chemical Works of Gedeon Richter's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chemical Works of Gedeon Richter 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chemical Works of Gedeon Richter's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Chemical Works of Gedeon Richter's 3-Year RORE % falls into.


RGEDF
94GF Score
Chemical Works of Gedeon Richter PLC RGEDF
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chemical Works of Gedeon Richter 3-Year RORE % Calculation

Chemical Works of Gedeon Richter's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 2.123-2.778 )/( 8.31-4.307 )
=-0.655/4.003
=-16.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -16.32 mean?
Chemical Works of Gedeon Richter (RGEDF) has a 3-Year RORE % of -16.32 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Chemical Works of Gedeon Richter and its competitors. According to the industry distribution chart, Chemical Works of Gedeon Richter ranks #612 out of 936 companies in the Drug Manufacturers industry, placing it in the top 65.4%.
Is Chemical Works of Gedeon Richter's 3-Year RORE % too high?
Chemical Works of Gedeon Richter's current 3-Year RORE % is -16.32. Based on the distribution chart, Chemical Works of Gedeon Richter ranks #612 out of 936 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Chemical Works of Gedeon Richter has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chemical Works of Gedeon Richter's 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chemical Works of Gedeon Richter ranks #612 out of 936 companies for 3-Year RORE %. This places Chemical Works of Gedeon Richter in the lower half of its industry. The industry median 3-Year RORE % is 3.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.08, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Chemical Works of Gedeon Richter and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemical Works of Gedeon Richter's current 3-Year RORE % is -16.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemical Works of Gedeon Richter stock overvalued right now?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter (RGEDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $35.24, compared to a current price of $39.76 — trading 12.8% above its estimated fair value. The current 3-Year RORE % is -16.32. Chemical Works of Gedeon Richter's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Chemical Works of Gedeon Richter (RGEDF), the current 3-Year RORE % is -16.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chemical Works of Gedeon Richter (RGEDF) Overvalued in 2026?

Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued. The current stock price of $39.76 is trading 12.8% above its estimated GF Value™ of $35.24. GuruFocus considers Chemical Works of Gedeon Richter to be Modestly Overvalued.

Key valuation signals for RGEDF:

  • 3-Year RORE %: -16.32
  • GF Value™: $35.24 vs. price of $39.76 (12.8% above fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the RGEDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chemical Works of Gedeon Richter Business Description

Address Gyomroi ut 19-21, Budapest, HUN, 1103
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
94GF Score

Get the complete analysis for RGEDF

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.76
Price
$35.24
GF Value